Azenta Q2 Earnings Call Highlights
Key takeaways
- 5 medical stocks growing earnings by triple digits
- “Candidly, we are not satisfied with our second quarter results,” President and CEO John Marotta said.
- → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries
Azenta Q2 Earnings Call Highlights Market Beat Wed, May 6, 2026 at 9:55 PM GMT+7 8 min read AZTA Azenta logo Key Points Azenta said Q2 results fell short of expectations with organic revenue down ~3%, reported revenue of $145 million, adjusted EBITDA margin of 5.4% and a non‑GAAP loss of $0.04 per share, which management blamed on execution shortfalls and cautious North American demand.
The company took large non‑cash impairments—$112.4 million for Multiomics and $36.6 million for Sample Management Solutions—and cut fiscal 2026 guidance to $603m–$621m reported revenue with organic revenue now expected to be down ~2% to up ~1% year‑over‑year.
Azenta ends the quarter with a strong liquidity position—$565 million in cash and marketable securities and no debt—and is implementing operational fixes (Azenta Business System, engineering restructuring, new Multiomics president, and automated‑store remediation) to improve execution and margins.